Human papillomaviruses and other biological markers in cervical cancer.

K. V. Shah

Research output: Contribution to journalArticle

Abstract

The presence of HPV DNA in the genital tract and the genotype of the infecting HPV are now widely employed as biochemical markers in epidemiological studies of cervical cancer. Additional HPV markers could be utilized in future investigations. The amount of HPV DNA is likely to be higher in case specimens than in control specimens; viral genome would be integrated frequently in cases but almost never in controls; and early region transcripts may be relatively more abundant in cases than in controls. When valid serological markers for past HPV infection become available (very likely, antibodies to HPV capsid proteins), they will be useful to estimate lifetime exposure to HPVs. Serological markers for HPV-associated neoplasia (very likely, antibodies to early proteins) may prove useful for surveillance and have prognostic value. A serological marker capable of detecting past herpes simplex virus 2 infection would permit an analysis of the role of this virus in cervical cancer, either as an independent risk factor or in interaction with HPVs. Other possible biomarkers include activation of oncogenes and inactivation of tumour-suppressor genes, assays for serum micronutrients, and analysis of leukocytes for HLA antigens; these should provide insights into the sequence of events that lead to cervical cancer and help to explain the geographic distribution of the disease.

Original languageEnglish (US)
Pages (from-to)209-218
Number of pages10
JournalIARC scientific publications
Issue number119
StatePublished - 1992

Fingerprint

Uterine Cervical Neoplasms
Biomarkers
HLA Antigens
Human Herpesvirus 2
Antibodies
Micronutrients
Viral Genome
DNA
Capsid Proteins
Virus Diseases
Tumor Suppressor Genes
Oncogenes
Epidemiologic Studies
Genotype
Viruses
Infection
Serum
Neoplasms
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Human papillomaviruses and other biological markers in cervical cancer. / Shah, K. V.

In: IARC scientific publications, No. 119, 1992, p. 209-218.

Research output: Contribution to journalArticle

@article{3ae91aa6394f49bc8ff1f125713ce87f,
title = "Human papillomaviruses and other biological markers in cervical cancer.",
abstract = "The presence of HPV DNA in the genital tract and the genotype of the infecting HPV are now widely employed as biochemical markers in epidemiological studies of cervical cancer. Additional HPV markers could be utilized in future investigations. The amount of HPV DNA is likely to be higher in case specimens than in control specimens; viral genome would be integrated frequently in cases but almost never in controls; and early region transcripts may be relatively more abundant in cases than in controls. When valid serological markers for past HPV infection become available (very likely, antibodies to HPV capsid proteins), they will be useful to estimate lifetime exposure to HPVs. Serological markers for HPV-associated neoplasia (very likely, antibodies to early proteins) may prove useful for surveillance and have prognostic value. A serological marker capable of detecting past herpes simplex virus 2 infection would permit an analysis of the role of this virus in cervical cancer, either as an independent risk factor or in interaction with HPVs. Other possible biomarkers include activation of oncogenes and inactivation of tumour-suppressor genes, assays for serum micronutrients, and analysis of leukocytes for HLA antigens; these should provide insights into the sequence of events that lead to cervical cancer and help to explain the geographic distribution of the disease.",
author = "Shah, {K. V.}",
year = "1992",
language = "English (US)",
pages = "209--218",
journal = "IARC (International Agency for Research on Cancer) Scientific Publications",
issn = "0300-5038",
publisher = "IARC",
number = "119",

}

TY - JOUR

T1 - Human papillomaviruses and other biological markers in cervical cancer.

AU - Shah, K. V.

PY - 1992

Y1 - 1992

N2 - The presence of HPV DNA in the genital tract and the genotype of the infecting HPV are now widely employed as biochemical markers in epidemiological studies of cervical cancer. Additional HPV markers could be utilized in future investigations. The amount of HPV DNA is likely to be higher in case specimens than in control specimens; viral genome would be integrated frequently in cases but almost never in controls; and early region transcripts may be relatively more abundant in cases than in controls. When valid serological markers for past HPV infection become available (very likely, antibodies to HPV capsid proteins), they will be useful to estimate lifetime exposure to HPVs. Serological markers for HPV-associated neoplasia (very likely, antibodies to early proteins) may prove useful for surveillance and have prognostic value. A serological marker capable of detecting past herpes simplex virus 2 infection would permit an analysis of the role of this virus in cervical cancer, either as an independent risk factor or in interaction with HPVs. Other possible biomarkers include activation of oncogenes and inactivation of tumour-suppressor genes, assays for serum micronutrients, and analysis of leukocytes for HLA antigens; these should provide insights into the sequence of events that lead to cervical cancer and help to explain the geographic distribution of the disease.

AB - The presence of HPV DNA in the genital tract and the genotype of the infecting HPV are now widely employed as biochemical markers in epidemiological studies of cervical cancer. Additional HPV markers could be utilized in future investigations. The amount of HPV DNA is likely to be higher in case specimens than in control specimens; viral genome would be integrated frequently in cases but almost never in controls; and early region transcripts may be relatively more abundant in cases than in controls. When valid serological markers for past HPV infection become available (very likely, antibodies to HPV capsid proteins), they will be useful to estimate lifetime exposure to HPVs. Serological markers for HPV-associated neoplasia (very likely, antibodies to early proteins) may prove useful for surveillance and have prognostic value. A serological marker capable of detecting past herpes simplex virus 2 infection would permit an analysis of the role of this virus in cervical cancer, either as an independent risk factor or in interaction with HPVs. Other possible biomarkers include activation of oncogenes and inactivation of tumour-suppressor genes, assays for serum micronutrients, and analysis of leukocytes for HLA antigens; these should provide insights into the sequence of events that lead to cervical cancer and help to explain the geographic distribution of the disease.

UR - http://www.scopus.com/inward/record.url?scp=0026438479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026438479&partnerID=8YFLogxK

M3 - Article

C2 - 1330911

AN - SCOPUS:0026438479

SP - 209

EP - 218

JO - IARC (International Agency for Research on Cancer) Scientific Publications

JF - IARC (International Agency for Research on Cancer) Scientific Publications

SN - 0300-5038

IS - 119

ER -